Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients
L Abramowitz, N Mathieu, F Roudot-Thoraval, N Lemarchand, P Bauer, C Hennequin, E Mitry, C Romelaer, T Aparicio, I Sobhani, L Abramowitz, N Mathieu, F Roudot-Thoraval, N Lemarchand, P Bauer, C Hennequin, E Mitry, C Romelaer, T Aparicio, I Sobhani
Abstract
Background: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
Aim: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
Methods: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
Results: In all, 151 patients (44 HIV+, 107 HIV-) were reviewed retrospectively for 27 (median of 16-44) months. HIV+ patients were male (100% vs. 27%, P < 0.001) and younger (45 vs. 62 years old, P < 0.001) than HIV- patients. No significant differences were observed in the tumour stage, pelvic radiotherapy dose or concomitant chemotherapy, according to the HIV status. After chemoradiotherapy, similar numbers of HIV+ and HIV- patients had grade III-IV toxicity. A complete response was obtained in 82% and 75% (N.S.) of cases, respectively. The disease-free survival rates were 77% and 67% (N.S.) and the overall survival rates were 85% and 84% (N.S.), respectively, after 3 years of follow-up. Duration of HIV infection, viral load and CD4 count had no effect on the survival rate of HIV+ patients with EAC.
Conclusions: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients. Therefore, the same therapeutic guidelines should be applied to both populations.
Source: PubMed